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June Supplement 201184S AbstractsMethods: Human aortic smooth muscle cells
(HASMC) were transfected with poly(B-amino ester) bio-
degradable polymers (Stemfect™) conjugated to fluores-
cently labeled GAPDH or negative control (NC) siRNAs.
Increasing polymer and siRNA concentrations were tested
for optimal transfection efficiency. Conjugate endocytosis
was confirmed by fluorescent microscopy, and gene silenc-
ing was assayed by qPCR normalized to 18S.
Results: Cellular translocation of the bioconjugates
was visible 24 and 48 hours after transfection beginning
with a 1.3l polymer: 200pmol siRNA conjugate. At 48
hours after transfection, efficient gene silencing was
achieved in a polymer concentration dependent manner,
independent of increasing siRNA concentrations. The
highest rate of GAPDH silencing was 844% vs. NC (n5,
P0.05), achieved with a 3.9l polymer: 200pmol siRNA
conjugate.
Conclusions: HASMCs were successfully transfected
using polymeric bioconjugates. Future studies will expand
on this method of gene therapy for transfection of whole
vessel segments and in vivo animal models of vascular
disease. This may provide new clinical options for genetic
therapy in the prevention of peripheral vascular
pathologies.
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Possible Involvement of Notch Signaling in the Mech-
anism of Buerger’s Disease
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tomu Ihara, Akihiko Hori, Hiroshi Banno, Masayoshi Ko-
bayashi, Kiyohito Yamamoto, Kimihiro Komori. Division
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Objectives: Arteries suffered from Buerger’s disease
were histologically reported an endarteritis that is intro-
duced T-cell mediated cellular immunity and B-cell medi-
ated humoral immunity associated with activation of mac-
rophages or dendritic cells in the intima. Several authors
have described that Notch signaling pathway coordinates
the interaction between inflammation and angiogenesis
under ischemic conditions. However, little information is
available about the relationship between Buerger’s disease
and Notch signaling pathway.
Methods: Sixty-nine specimens from 24 patients, in
whom Buerger’s disease was diagnosed on the basis of our
clinical criteria (Shionoya’s criteria) between 1980 and
2009 at Nagoya University Hospital, were studied (group
A). Controls were 65 specimens from 24 patients, who iere suffered from arteriosclerosis obliterans in the same
eriod (group B). Immunohistochemically, two groups are
nalyzed for expression of Notch signaling pathway: anti-
otch-1, the Notch-1 ligand anti-Jagged-1, the down-
tream Notch-1 target anti-Hes-1. Immunohistochemical
echnique is performed using a Ventana Discovery XT
mmunostainer. Each sample is viewed at 200x magnifica-
ion high-power fields, and 20 randomly selected fields are
nalyzed in each section.
Results: Notch-1, Jagged-1, and Hes-1 are more ex-
ressed in infiltrating cells in the intima in group A than in
roup B (Notch-1(%):8.4-0.76 versus 1.3-0.43,
0.001; Jagged-1:9.3-1.1 versus 5.2-1.1, p0.03;
es-1:8.2-0.69 versus 1.5-0.50, p0.001).
Conclusions: Several studies reported that Notch sig-
aling pathway coordinates the interaction between inflam-
ation and angiogenesis under ischemic conditions. To
ur knowledge, our findings are the first demonstration
hat Notch signaling pathwaymay contribute to underlying
he mechanism of endarteritis of the arteries suffered from
uerger7s disease.
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S212.
eri-Adventitial Delivery of a Nanoparticle Albumin-
ound Rapamycin Reduces Luminal Stenosis in a Por-
ine Femoral Artery Balloon Injury Model
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ichael S. Conte1, Christopher Owens1. 1University of
alifornia San Francisco, San Francisco, CA; 2Mercator
edsystems, San Leandro, CA
Objectives: Rapamycin-based drug delivery platforms
n peripheral arteries have proven to be safe and feasible but
ot effective in reducing intimal hyperplasia (IH).We
ought to determine whether peri-adventitial delivery of
apamycin would be effective in reducing luminal stenosis
n a porcine balloon injury model.
Methods: Femoral artery injury sites were created with
pressure-controlled endothelial denudation. Two weeks
ater,a 20-30% overstretch of the injury sites was per-
ormed. Under fluoroscopy, nanoparticle albumin-bound
NAB) rapamycin (Abraxis Bioscience) (5 or 500 g) or
ehicle was delivered to the adventitia using a micro-infu-
ion catheter (Mercator MedSystems). After 28 days,the
rteries were harvested. The primary outcome was histo-
orphometric evidence of luminal stenosis and remodel-ng. Vessel injury was scored on a validated ordinal scale.
